3P Biopharmaceuticals appoints Kenneth McMahon as Head of Quality Control

Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments.

3P Biopharmaceuticals (3P), a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) appoints a new member as head of quality control.

Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments. He joined 3P with the objective of controlling and ensuring the correct quality of the manufactured products as well as compliance with the approved safety criteria.
He began his professional career in quality control at Genzyme (now Sanofi). In 2015 he joined the quality department at Bristol Myers Squibbs and since then he has continued to develop his knowledge and skills in the field of pharmaceutical quality.

After that, he worked for 4 years in positions of responsibility within the Quality Assurance and Quality Control departments at Samsung Biologics.
His professional career has been developed in GMP environments, and he is an expert in the design, development, and implementation of pharmaceutical quality systems, as well as in the management and quality control of pharmaceutical products.

3P Biopharmaceuticals appoints Kenneth McMahon as Head of Quality Control

“Joining a company like 3P is a fantastic opportunity to further develop my career and to be able to move back to Europe. I look forward to contributing successfully to their quality strategy”. Kenneth said on his arrival at the Noáin-based company.
Dámaso Molero, CEO of 3P Biopharmaceuticals said: “As an international company, we are excited to welcome Kenneth to our team. His extensive experience in senior quality positions will undoubtedly help us to strengthen the area to continue providing a high level of service”.

Therefore, with this new addition to the quality department, 3P continues its growth plan and consolidates its competitive position as one of the leading CDMOs in Europe.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals among the 500 fastest growing companies in Spain

Published: 19th December 2022
This is the first year the company appears in the ranking established by CEPYME for 500 companies that lead business growth in Spain.
Read more

3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary.

Published: 1st December 2022
The event gathered an audience of more than 150 people and was attended by Juan Cruz Cigudosa, Councillor for University, Innovation, and Digital Transformation.
Read more

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.